Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Seth Page (NPI 1518974948)

Field	Value
Entity Type	Individual
Organization	Seth Page
Address	1000 Hospital Dr
City	Mcpherson
State	KS
ZIP	67460
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 1, 2006

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This profile is effectively single‑payer Medicare: lifetime Medicare revenue totals $1.9M and there is no Medicaid billing on file. The provider’s top three Medicare codes account for 68.6% of that Medicare revenue, indicating concentrated dependence on a few high‑revenue services and drugs.

Taxonomy and code mix align with an infusion‑based hematology/oncology practice: the largest revenue line is J9271 (pembrolizumab) with $808.4K revenue and 18.8K claims, followed by high volumes of oncology drug administration and supportive care codes such as 96413 (chemo administration) and G0498. The presence of PET/CT (78815) and multiple infusion add‑on codes (96417, 96365, 96367) reinforces that systemic therapy and associated imaging are central to clinical operations.

Revenue concentration is driven by a small set of oncology agents: J9271 represents $808.4K (46.1% of Medicare revenue), J0897 represents $264.6K (15.1%), and 78815 represents $129.7K (7.4%); these three together make up the precomputed 68.6% share. This pattern signals that a few high‑cost drugs and one imaging modality dominate the practice’s Medicare receipts.

Competitive standing varies by code: the provider’s J0897 volume ranks #558 of 10057 nationally (94th percentile, described as notably above typical national volume), indicating a comparatively large role in denosumab administration. By contrast, J9271 ranks #461 of 1841 (74th percentile) and 78815 ranks #1696 of 6566 (74th percentile), both characterized as typical, so pembrolizumab and PET/CT activity are in line with many peers rather than dominant.

Ambulatory evaluation & management activity is high relative to national peers: 99214 shows 821 claims and $74.7K revenue with a rank in the 96th percentile (notably above typical), 99213 has 702 claims and $42.1K revenue at the 97th percentile (notably above typical), and the new‑patient high‑level code 99205 is an extreme outlier at the 99th percentile with 173 claims and $26.5K revenue. Together these E/M volumes suggest a busy outpatient oncology clinic managing both many established visits and a disproportionately large share of high‑complexity new patient evaluations.

Multiple supportive‑care and biosimilar products appear in the mix, consistent with comprehensive oncology services: Q5108 (pegfilgrastim biosimilar) records 456 claims and $43.8K revenue (66th percentile, typical), J1627 (granisetron extended‑release) shows 8.7K claims and $43.5K revenue (63th percentile, typical), and Q5106 (epoetin biosimilar) contributes $9.1K revenue. These entries indicate routine use of growth factors and antiemetics alongside chemotherapy.

The provider shows notable remote/telephone encounter activity relative to peers: 99441 has 273 claims and $10.1K revenue ranked in the 98th percentile (notably above typical), and 99442 has 220 claims and $14.3K revenue at the 97th percentile. This suggests a higher‑than‑typical reliance on brief telephonic E/M codes in the Medicare population.

The NPI was enumerated on 2006-08-01 (~20 years ago), indicating long tenure in the Medicare program. That duration, combined with concentrated high‑volume administration of specific oncology drugs and elevated outpatient visit coding, is consistent with an established specialty practice focused on systemic cancer therapy and associated supportive care.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

84 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,800	$40	$808.4K
J0897	Injection, denosumab, 1 mg	14,700	$20	$264.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	120	$1,060	$129.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	820	$90	$74.7K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,180	$30	$71.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	570	$90	$53K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	460	$100	$43.8K
J1627	Injection, granisetron, extended-release, 0.1 mg	8,700	$10	$43.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	700	$60	$42.1K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	170	$150	$26.5K

Showing 1–10 of 84

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 84 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Seth Page — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

84 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	20	28,900	$40	$1.1M
J1568	11	10	3,690	$30	$129K
J0897	12	180	2,160	$20	$81.5K
J1627	12	10	15,500	$1	$78.7K
J1439	13	10	41,250	$1	$66.1K
Q5108	11	10	610	$100	$62.7K
78815	22	90	60	$490	$56K
J0185	12	20	25,220	$1	$34.8K
82306	83	160	40	$30	$27.1K
96413	17	80	80	$90	$26.3K

Showing 1–10 of 84

Related Providers

Other providers that share a Tax Identification Number (TIN) with Seth Page, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Seth Page, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Disability Supports Of The Great Plains, Inc.	KS	Home Health Agency	$0	$60M
Multi Community Diversified Services, Inc.	KS	Developmentally Disabled Services Day Training Agency	$0	$39.5M
New Beginnings Of Mcpherson, Inc.	KS	Rehabilitation Counselor	$0	$4.2M
Mcpherson Hospital, Inc.	KS	Rural Health Clinic/Center	$0	$2.5M
D & P Homecare, Inc.	KS	Home Health Agency	$0	$1.7M
Mcpherson Usd 418	KS	Local Education Agency (LEA)	$0	$991.6K
Multi Community Diversified Services, Inc.	KS	Case Management Agency	$0	$950.8K
Esther Rettig	KS	Ophthalmology Physician	$638.4K	$5.6K
James Larzalere	KS	Pediatric Adolescent Medicine Physician	$119.2K	$1.5K
Bradley Lunsford	KS	Physical Therapist	$113.3K	$0

Seth Page — Billing Profile & Reimbursement Data

Sign up for Seth Page — Billing Profile & Reimbursement Data policy alerts

Seth Page — Billing Profile & Reimbursement Data

Sign up for Seth Page — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References